antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2022-67-5-6-70-80antibiotics-930Research ArticleОБЗОРЫREVIEWSИммуногенность вакцин против SARS-CoV-2 у пациентов с ревматическими заболеваниямиImmunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseaseshttps://orcid.org/0000-0001-7091-2054БЕЛОВБ. С.BELOVB. B.

Белов Борис Сергеевич — д. м. н., заведующий лабораторией коморбидных инфекций и вакцинопрофилактики.ResearcherID: ABD-2219-2020eLIBRARY SPIN-код: 3298-4315Scopus Author ID: 7004592537

115522, г. Москва, Каширское шоссе, 34-А

Boris S. Belov — D. Sc. in medicine.Researcher ID: ABD-2219-2020eLIBRARY SPIN: 3298-4315Scopus Author ID: 7004592537

115522, Moscow, Kashirskoe highway, 34-A

belovbor@yandex.ruhttps://orcid.org/0000-0003-4327-6720МУРАВЬЕВАН. В.MURAVYEVAN. V.

Муравьева Наталья Валерьевна — к. м. н., научный сотрудник лаборатории коморбидных инфекций и вакцинопрофилактики. ResearcherID: AAF4853-2021eLIBRARY SPIN-код: 8418-4469Scopus Author ID: 57210263706

г. Москва

Natalia V. Muravyeva — Ph. D. in medicine. Researcher ID: AAF-4853-2021eLIBRARY SPIN: 8418-4469Scopus Author ID: 57210263706

Moscow

https://orcid.org/0000-0003-1040-313XКУЛИКОВА. Н.KULIKOVA. N.

Куликов Александр Николаевич — младший научный сотрудник лаборатории коморбидных инфекций и вакцинопрофилактики. eLIBRARY SPIN-код: 1512-0204Scopus Author ID: 57464168300

Москва

Aleksandr N. Kulikov — Junior Researcher at the Laboratory of Comorbid Infections and Vaccine Prevention. eLIBRARY SPIN: 1512-0204Scopus Author ID: 57464168300

Moscow

ФГБНУ НИИ ревматологии им. В. А. НасоновойРоссияV. A. Nasonova Research Institute of RheumatologyRussian Federation202209092022675-67080Copyright © БЕЛОВ Б.С., МУРАВЬЕВА Н.В., КУЛИКОВ А.Н., 20222022БЕЛОВ Б.С., МУРАВЬЕВА Н.В., КУЛИКОВ А.Н.BELOV B.B., MURAVYEVA N.V., KULIKOV A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/930

Проблема коронавирусной болезни 2019 (COVID-19) спустя два года по-прежнему сохраняет свою актуальность. В качестве одного из методов борьбы с текущей пандемией COVID-19 большинство экспертов предлагают широко использовать вакцинацию. Применение антиковидных вакцин у больных ревматическими заболеваниями поднимает ряд вопросов, связанных с эффективностью, иммуногенностью (особенно у пациентов, получающих иммуносупрессивную терапию) и безопасностью иммунизации. Исходя из этого весьма важен анализ данных по вышеназванным аспектам в режиме реального времени. В настоящем обзоре представлены результаты исследований последних двух лет по проблеме иммуногенности вакцинации против COVID-19 в ревматологии. Продемонстрирована способность ряда антиревматических препаратов оказывать (в различной степени) негативное влияние на поствакцинальный ответ. Интерпретация и сопоставление результатов исследований иммуногенности вакцин осложняются рядом факторов, связанных, как правило, с дизайном работ. В рамках рассматриваемой проблемы имеется ещё достаточное количество вопросов, ответы на которые должны быть получены в дальнейших исследованиях.

The problem of coronavirus disease 2019 (COVID-19) still remains relevant even now, after two years. As one of the methods of combating the current COVID-19 pandemic, most experts suggest the widespread use of vaccination. The use of anticovid vaccines in patients with rheumatic diseases raises a number of questions related to efficacy, immunogenicity (especially in patients receiving immunosuppressive therapy), as well as safety of immunization. With that in mind, it is very important to analyze the data on the above-mentioned aspects in real time. This review presents the results of studies on COVID-19 vaccination immunogenicity in rheumatology conducted over the past two years. The ability of a number of antirheumatic drugs to have a negative effect (to varying degrees) on the post-vaccination response has been demonstrated. Interpretation and comparison of the results of vaccine immunogenicity studies are complicated by a number of factors usually associated with the design of works. Within the framework of the problem under consideration, there are still a sufficient number of questions, the answers to which should be found in further research.

COVID-19иммуновоспалительные ревматические заболеваниявакцинацияиммуногенностьклинические рекомендацииCOVID-19immuno-inflammatory rheumatic diseasesvaccinationimmunogenicityclinical guidelinesReferencesAvailable at: https://extranet.who.int/pqweb/sites/default/files/documents/ Status_COVID_VAX_02April2022.pdf. Accessed: 15th May 2022Available at: https://extranet.who.int/pqweb/sites/default/files/documents/ Status_COVID_VAX_02April2022.pdf. Accessed: 15th May 2022Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed: 15th May 2022Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed: 15th May 2022van Assen S., Elkayam O., Agmon-Levin N. et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidencebased recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Autoimmun Rev. 2011 Apr; 10 (6): 341–352. doi:10.1016/j.autrev.2010.12.003.van Assen S., Elkayam O., Agmon-Levin N. et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidencebased recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Autoimmun Rev. 2011 Apr; 10 (6): 341–352. doi:10.1016/j.autrev.2010.12.003.Deepak P., Kim W., Paley M.A. et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med. 2021 Nov; 174 (11): 1572–1585. doi:10.7326/M21-1757.Deepak P., Kim W., Paley M.A. et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med. 2021 Nov; 174 (11): 1572–1585. doi:10.7326/M21-1757.Haberman R.H., Um S., Axelrad J.E. et al. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatol. 2022; 4 (6): e384–e387. doi:10.1016/S2665-9913(22)00069-8.Haberman R.H., Um S., Axelrad J.E. et al. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatol. 2022; 4 (6): e384–e387. doi:10.1016/S2665-9913(22)00069-8.Spiera R., Jinich S., Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021; 80 (10): 1357–1359. doi:10.1136/annrheumdis-2021-220604Spiera R., Jinich S., Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021; 80 (10): 1357–1359. doi:10.1136/annrheumdis-2021-220604Boyarsky B.J., Ruddy J.A., Connolly C.M. et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021; 80 (8): 1098–1099. doi:10.1136/annrheumdis-2021-220289.Boyarsky B.J., Ruddy J.A., Connolly C.M. et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021; 80 (8): 1098–1099. doi:10.1136/annrheumdis-2021-220289.Fabris M., De Marchi G., Domenis R. et al. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. J Autoimmun. 2022; 129: 102827. doi:10.1016/j.jaut.2022.102827.Fabris M., De Marchi G., Domenis R. et al. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. J Autoimmun. 2022; 129: 102827. doi:10.1016/j.jaut.2022.102827.Geisen U.M., Berner D.K., Tran F. et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021; 80 (10): 1306–1311. doi:10.1136/annrheumdis2021-220272.Geisen U.M., Berner D.K., Tran F. et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021; 80 (10): 1306–1311. doi:10.1136/annrheumdis2021-220272.Prendecki M., Clarke C., Edwards H. et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis. 2021; 80 (10): 1322–1329. doi:10.1136/annrheumdis2021-220626.Prendecki M., Clarke C., Edwards H. et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis. 2021; 80 (10): 1322–1329. doi:10.1136/annrheumdis2021-220626.Izmirly P.M., Kim M.Y., Samanovic M. et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol. 2022; 74 (2): 284–294. doi:10.1002/art.41937.Izmirly P.M., Kim M.Y., Samanovic M. et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol. 2022; 74 (2): 284–294. doi:10.1002/art.41937.Moor M.B., Suter-Riniker F., Horn M.P. et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021; 3 (11): e789–e797. doi:10.1016/S2665-9913(21)00251-4.Moor M.B., Suter-Riniker F., Horn M.P. et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021; 3 (11): e789–e797. doi:10.1016/S2665-9913(21)00251-4.Chiang T.P., Connolly C.M., Ruddy J.A. et al. Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021; 80 (10): 1365–1366. doi:10.1136/annrheumdis-2021-221145.Chiang T.P., Connolly C.M., Ruddy J.A. et al. Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021; 80 (10): 1365–1366. doi:10.1136/annrheumdis-2021-221145.Medeiros-Ribeiro A.C., Aikawa N.E., Saad C.G.S. et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021; 27 (10): 1744–1751. doi:10.1038/s41591-021-01469-5.Medeiros-Ribeiro A.C., Aikawa N.E., Saad C.G.S. et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021; 27 (10): 1744–1751. doi:10.1038/s41591-021-01469-5.Bugatti S., De Stefano L., Balduzzi S. et al. Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. Ann Rheum Dis. 2021; 80 (12): 1635–1638. doi:10.1136/annrheumdis-2021-220862.Bugatti S., De Stefano L., Balduzzi S. et al. Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. Ann Rheum Dis. 2021; 80 (12): 1635–1638. doi:10.1136/annrheumdis-2021-220862.Simon D., Tascilar K., Fagni F. et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021; 80 (10): 1312–1316. doi:10.1136/annrheumdis-2021-220461.Simon D., Tascilar K., Fagni F. et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021; 80 (10): 1312–1316. doi:10.1136/annrheumdis-2021-220461.Verstappen G.M., de Wolff L., Arends S. et al. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome. RMD Open. 2022; 8 (1): e002265. doi:10.1136/rmdopen-2022-002265.Verstappen G.M., de Wolff L., Arends S. et al. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome. RMD Open. 2022; 8 (1): e002265. doi:10.1136/rmdopen-2022-002265.Szebeni G.J., Gémes N., Honfi D. et al. Humoral and cellular immunogenicity and safety of five different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases in remission or with low disease activity and in healthy controls: a single center study. Front Immunol. 2022 Mar; 13: 846248. doi:10.3389/fimmu.2022.846248.Szebeni G.J., Gémes N., Honfi D. et al. Humoral and cellular immunogenicity and safety of five different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases in remission or with low disease activity and in healthy controls: a single center study. Front Immunol. 2022 Mar; 13: 846248. doi:10.3389/fimmu.2022.846248.Kashiwado Y., Kimoto Y., Sawabe T. et al. Antibody response to SARSCoV-2 mRNA vaccines in patients with rheumatic diseases in japan: interim analysis of a multicenter cohort study. Mod Rheumatol. 2022 Apr 12: roac030. doi:10.1093/mr/roac030.Kashiwado Y., Kimoto Y., Sawabe T. et al. Antibody response to SARSCoV-2 mRNA vaccines in patients with rheumatic diseases in japan: interim analysis of a multicenter cohort study. Mod Rheumatol. 2022 Apr 12: roac030. doi:10.1093/mr/roac030.Ferri C., Ursini F., Gragnani L. et al. Impaired immunogenicity to COVID19 vaccines in autoimmune systemic diseases. High prevalence of nonresponse in different patients' subgroups. J Autoimmun. 2021; 125: 102744. doi:10.1016/j.jaut.2021.102744.Ferri C., Ursini F., Gragnani L. et al. Impaired immunogenicity to COVID19 vaccines in autoimmune systemic diseases. High prevalence of nonresponse in different patients' subgroups. J Autoimmun. 2021; 125: 102744. doi:10.1016/j.jaut.2021.102744.Braun-Moscovici Y., Kaplan M., Braun M. et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021; 80 (10): 1317–1321. doi:10.1136/annrheumdis-2021-220503.Braun-Moscovici Y., Kaplan M., Braun M. et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021; 80 (10): 1317–1321. doi:10.1136/annrheumdis-2021-220503.Boekel L., Steenhuis M., Hooijberg F. et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021; 3 (11): e778–e788. doi:10.1016/S2665-9913(21)00222-8.Boekel L., Steenhuis M., Hooijberg F. et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021; 3 (11): e778–e788. doi:10.1016/S2665-9913(21)00222-8.Krasselt M., Wagner U., Nguyen P. et al. Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology (Oxford). 2022; 61 (S12): S1180–S1188. doi:10.1093/rheumatology/keac089.Krasselt M., Wagner U., Nguyen P. et al. Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology (Oxford). 2022; 61 (S12): S1180–S1188. doi:10.1093/rheumatology/keac089.Frey S., Chiang T.P., Connolly C.M. et al. Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease. Lancet Rheumatol. 2022; 4 (4): e241–e243. doi:10.1016/S2665-9913(21)00417-3.Frey S., Chiang T.P., Connolly C.M. et al. Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease. Lancet Rheumatol. 2022; 4 (4): e241–e243. doi:10.1016/S2665-9913(21)00417-3.van der Togt C.J.T., Ten Cate D.F., den Broeder N. et al. Humoral response to Coronavirus Disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2022; 61 (S12): S1175–S1179. doi:10.1093/rheumatology/keac206.van der Togt C.J.T., Ten Cate D.F., den Broeder N. et al. Humoral response to Coronavirus Disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2022; 61 (S12): S1175–S1179. doi:10.1093/rheumatology/keac206.Tien N., Chang Y.C., Chen P.K. et al. The Immunogenicity and safety of three types of SARS-CoV-2 vaccines in adult patients with immune-mediated inflammatory diseases: a longitudinal cohort study. Biomedicines. 2022; 10 (4): 911. doi:10.3390/biomedicines10040911.Tien N., Chang Y.C., Chen P.K. et al. The Immunogenicity and safety of three types of SARS-CoV-2 vaccines in adult patients with immune-mediated inflammatory diseases: a longitudinal cohort study. Biomedicines. 2022; 10 (4): 911. doi:10.3390/biomedicines10040911.Troldborg A., Thomsen M.K., Bartels L.E. et al. Time since Rituximab treatment is essential for developing a humoral response to COVID-19 mRNA vaccines in patients with rheumatic diseases. J Rheumatol. 2022; 49 (6): 644–649. doi:10.3899/jrheum.211152.Troldborg A., Thomsen M.K., Bartels L.E. et al. Time since Rituximab treatment is essential for developing a humoral response to COVID-19 mRNA vaccines in patients with rheumatic diseases. J Rheumatol. 2022; 49 (6): 644–649. doi:10.3899/jrheum.211152.Ahmed S., Mehta P., Paul A. et al. Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort. Ann Rheum Dis. 2022; 81 (6): 868–874. doi:10.1136/annrheumdis-2021-221922.Ahmed S., Mehta P., Paul A. et al. Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort. Ann Rheum Dis. 2022; 81 (6): 868–874. doi:10.1136/annrheumdis-2021-221922.Mandl P., Tobudic S., Haslacher H. et al. Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study. Ann Rheum Dis. 2022; 81 (7): 1017–1022. doi:10.1136/annrheumdis-2021-221788.Mandl P., Tobudic S., Haslacher H. et al. Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study. Ann Rheum Dis. 2022; 81 (7): 1017–1022. doi:10.1136/annrheumdis-2021-221788.Moyon Q., Sterlin D., Miyara M. et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis. 2022 Apr; 81 (4): 575–583. doi:10.1136/annrheumdis-2021-221097.Moyon Q., Sterlin D., Miyara M. et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis. 2022 Apr; 81 (4): 575–583. doi:10.1136/annrheumdis-2021-221097.Saleem B., Ross R.L., Bissell L.A. et al. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses. RMD Open. 2022 Mar; 8 (1): e002050. doi:10.1136/rmdopen-2021-002050.Saleem B., Ross R.L., Bissell L.A. et al. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses. RMD Open. 2022 Mar; 8 (1): e002050. doi:10.1136/rmdopen-2021-002050.Araujo C.S.R., Medeiros-Ribeiro A.C., Saad C.G.S. et al. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Ann Rheum Dis. 2022; 81 (6): 889–897. doi:10.1136/annrheumdis-2021-221916.Araujo C.S.R., Medeiros-Ribeiro A.C., Saad C.G.S. et al. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Ann Rheum Dis. 2022; 81 (6): 889–897. doi:10.1136/annrheumdis-2021-221916.Madelon N., Lauper K., Breville G. et al. Robust T cell responses in antiCD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. 2021 Nov 17; ciab954. doi:10.1093/cid/ciab954.Madelon N., Lauper K., Breville G. et al. Robust T cell responses in antiCD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. 2021 Nov 17; ciab954. doi:10.1093/cid/ciab954.Benucci M., Damiani A., Infantino M. et al. Vaccination for SARS-CoV-2 in patients with psoriatic arthritis: can therapy affect the immunological response? Front Med (Lausanne). 2022 Feb 28; 9: 811829. doi:10.3389/fmed.2022.811829. PMID:35295608; PMCID: PMC8918942.Benucci M., Damiani A., Infantino M. et al. Vaccination for SARS-CoV-2 in patients with psoriatic arthritis: can therapy affect the immunological response? Front Med (Lausanne). 2022 Feb 28; 9: 811829. doi:10.3389/fmed.2022.811829. PMID:35295608; PMCID: PMC8918942.Ammitzbøll C., Bartels L.E., Bøgh Andersen J. et al. Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol. 2021 Sep; 3 (9): 622–628. doi:10.1002/acr2.11299. Epub 2021 Jul 17. PMID:34273260; PMCID: PMC8426741.Ammitzbøll C., Bartels L.E., Bøgh Andersen J. et al. Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol. 2021 Sep; 3 (9): 622–628. doi:10.1002/acr2.11299. Epub 2021 Jul 17. PMID:34273260; PMCID: PMC8426741.Sugihara K., Wakiya R., Shimada H. et al. Immunogenicity against the BNT162b2 mRNA COVID-19 vaccine in rheumatic disease patients receiving immunosuppressive therapy. Intern Med. 2022; 61 (13): 1953–1958. doi:10.2169/internalmedicine.9223-21.Sugihara K., Wakiya R., Shimada H. et al. Immunogenicity against the BNT162b2 mRNA COVID-19 vaccine in rheumatic disease patients receiving immunosuppressive therapy. Intern Med. 2022; 61 (13): 1953–1958. doi:10.2169/internalmedicine.9223-21.Simader E., Tobudic S., Mandl P. et al. Importance of the second SARSCoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. Ann Rheum Dis. 2022 Mar; 81 (3): 416–421. doi:10.1136/annrheumdis-2021-221347.Simader E., Tobudic S., Mandl P. et al. Importance of the second SARSCoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. Ann Rheum Dis. 2022 Mar; 81 (3): 416–421. doi:10.1136/annrheumdis-2021-221347.Hadjadj J., Planas D., Ouedrani A. et al. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann Rheum Dis. 2022; 81 (5): 720–728. doi:10.1136/annrheumdis-2021-221508.Hadjadj J., Planas D., Ouedrani A. et al. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann Rheum Dis. 2022; 81 (5): 720–728. doi:10.1136/annrheumdis-2021-221508.Connolly C.M., Teles M., Frey S. et al. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Ann Rheum Dis. 2022; 81 (2): 291–293. doi:10.1136/annrheumdis-2021-221206.Connolly C.M., Teles M., Frey S. et al. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Ann Rheum Dis. 2022; 81 (2): 291–293. doi:10.1136/annrheumdis-2021-221206.Durán J., Burgos P.I., Le Corre N. et al. Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine. Ann Rheum Dis. 2022 Apr 13: annrheumdis-2022-222189. doi:10.1136/annrheumdis-2022-222189.Durán J., Burgos P.I., Le Corre N. et al. Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine. Ann Rheum Dis. 2022 Apr 13: annrheumdis-2022-222189. doi:10.1136/annrheumdis-2022-222189.Aikawa N.E., Kupa L.V.K., Medeiros-Ribeiro A.C. et al. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Ann Rheum Dis. 2022 Mar 11. doi:10.1136/annrheumdis-2021-222096.Aikawa N.E., Kupa L.V.K., Medeiros-Ribeiro A.C. et al. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Ann Rheum Dis. 2022 Mar 11. doi:10.1136/annrheumdis-2021-222096.Jyssum I., Kared H., Tran T.T. et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2022; 4 (3): e177–e187. doi:10.1016/S2665-9913(21)00394-5.Jyssum I., Kared H., Tran T.T. et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2022; 4 (3): e177–e187. doi:10.1016/S2665-9913(21)00394-5.Wieske L., van Dam K.P.J., Steenhuis M. et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immunemediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022 Mar; 4 (5): e338–e350. doi:10.1016/S2665-9913(22)00034-0.Wieske L., van Dam K.P.J., Steenhuis M. et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immunemediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022 Mar; 4 (5): e338–e350. doi:10.1016/S2665-9913(22)00034-0.Simon D., Tascilar K., Fagni F. et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease. Ann Rheum Dis. 2022; 81 (7): 1023–1027. doi:10.1136/annrheumdis-2021-221554.Simon D., Tascilar K., Fagni F. et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease. Ann Rheum Dis. 2022; 81 (7): 1023–1027. doi:10.1136/annrheumdis-2021-221554.Furer V., Eviatar T., Zisman D. et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021; 80 (10): 1330–1338. doi:10.1136/annrheumdis-2021-220647.Furer V., Eviatar T., Zisman D. et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021; 80 (10): 1330–1338. doi:10.1136/annrheumdis-2021-220647.Arumahandi de Silva A.N., Frommert L.M., Albach F.N. et al. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Ann Rheum Dis. 2022; 81 (6): 881–888. doi:10.1136/annrheumdis-2021-221876.Arumahandi de Silva A.N., Frommert L.M., Albach F.N. et al. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Ann Rheum Dis. 2022; 81 (6): 881–888. doi:10.1136/annrheumdis-2021-221876.Kennedy N.A., Lin S., Goodhand J.R. et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARSCoV-2 vaccines in patients with IBD. Gut. 2021; 70 (10): 1884–1893. doi:10.1136/gutjnl-2021-324789.Kennedy N.A., Lin S., Goodhand J.R. et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARSCoV-2 vaccines in patients with IBD. Gut. 2021; 70 (10): 1884–1893. doi:10.1136/gutjnl-2021-324789.Geisen U.M., Sümbül M., Tran F. et al. Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD Open. 2021 Dec; 7 (3): e002008. doi:10.1136/rmdopen-2021-002008.Geisen U.M., Sümbül M., Tran F. et al. Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD Open. 2021 Dec; 7 (3): e002008. doi:10.1136/rmdopen-2021-002008.Curtis J.R., Johnson S.R., Anthony D.D. et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol. 2022 May; 74 (5): e21–e36. doi:10.1002/art.42109.Curtis J.R., Johnson S.R., Anthony D.D. et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol. 2022 May; 74 (5): e21–e36. doi:10.1002/art.42109.Assawasaksakul T., Sathitratanacheewin S., Vichaiwattana P. et al. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series. RMD Open. 2021 Dec; 7 (3): e002019. doi:10.1136/rmdopen2021-002019.Assawasaksakul T., Sathitratanacheewin S., Vichaiwattana P. et al. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series. RMD Open. 2021 Dec; 7 (3): e002019. doi:10.1136/rmdopen2021-002019.Auroux M., Laurent B., Coste B. et al. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: a cohort study and a systematic review with meta-analysis. Joint Bone Spine. 2022 Apr 28; 89 (5): 105380. doi:10.1016/j.jbspin.2022.105380.Auroux M., Laurent B., Coste B. et al. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: a cohort study and a systematic review with meta-analysis. Joint Bone Spine. 2022 Apr 28; 89 (5): 105380. doi:10.1016/j.jbspin.2022.105380.Landewé R.B.M., Kroon F.P.B., Alunno A. et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. 2022 Feb 23. doi:10.1136/annrheumdis-2021-222006.Landewé R.B.M., Kroon F.P.B., Alunno A. et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. 2022 Feb 23. doi:10.1136/annrheumdis-2021-222006.Santosa A., Xu C., Arkachaisri T. et al. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists. Int J Rheum Dis. 2021; 24 (6): 746–757. doi:10.1111/1756-185X.14107.Santosa A., Xu C., Arkachaisri T. et al. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists. Int J Rheum Dis. 2021; 24 (6): 746–757. doi:10.1111/1756-185X.14107.Hazlewood G.S., Pardo J.P., Barnabe C. et al. Canadian rheumatology association recommendation for the use of COVID-19 vaccination for patients with autoimmune rheumatic diseases. J Rheumatol. 2021; 48 (8): 1330–1339. doi:10.3899/jrheum.210288.Hazlewood G.S., Pardo J.P., Barnabe C. et al. Canadian rheumatology association recommendation for the use of COVID-19 vaccination for patients with autoimmune rheumatic diseases. J Rheumatol. 2021; 48 (8): 1330–1339. doi:10.3899/jrheum.210288.Tavares A.C.F.M.G., de Melo A.K.G., Cruz V.A. et al. Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force. Adv Rheumatol. 2022; 62 (1): 3. doi:10.1186/s42358-022-00234-7.Tavares A.C.F.M.G., de Melo A.K.G., Cruz V.A. et al. Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force. Adv Rheumatol. 2022; 62 (1): 3. doi:10.1186/s42358-022-00234-7.Park J.K., Lee E.B., Shin K. et al. Korean college of rheumatology task force for COVID-19 vaccine guidance for patients with autoimmune inflammatory rheumatic diseases. COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: Clinical Guidance of the Korean College of Rheumatology. J Korean Med Sci. 2021; 36 (12): e95. doi:10.3346/jkms.2021.36.e95.Park J.K., Lee E.B., Shin K. et al. Korean college of rheumatology task force for COVID-19 vaccine guidance for patients with autoimmune inflammatory rheumatic diseases. COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: Clinical Guidance of the Korean College of Rheumatology. J Korean Med Sci. 2021; 36 (12): e95. doi:10.3346/jkms.2021.36.e95.Насонов Е.Л., Лила А.М., Мазуров В.И. и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021; 59 (3): 239–254. https://doi.org/10.47360/1995-4484-2021-239-254.Nasonov E.L., Lila A.M., Mazurov V.I. et al. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2021; 59 (3): 239–254. https://doi.org/10.47360/1995-4484-2021-239-254. (in Russian)COVID-19 Vaccine Clinical Guidance Summary for patients with rheumatic and musculoskeletal diseases. Version 5. Revised January 28, 2022. Available at: https://www.rheumatology.org/Practice-Quality/ClinicalSupport/COVID-19-Guidance. Accessed: 17th May 2022.COVID-19 Vaccine Clinical Guidance Summary for patients with rheumatic and musculoskeletal diseases. Version 5. Revised January 28, 2022. Available at: https://www.rheumatology.org/Practice-Quality/ClinicalSupport/COVID-19-Guidance. Accessed: 17th May 2022.Widdifield J., Kwong J.C., Chen S. et al. Vaccine effectiveness against SARSCoV-2 infection and severe outcomes among individuals with immunemediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. Lancet Rheumatol. 2022; 4 (6): e430–e440. doi:10.1016/S2665-9913(22)00096-0.Widdifield J., Kwong J.C., Chen S. et al. Vaccine effectiveness against SARSCoV-2 infection and severe outcomes among individuals with immunemediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. Lancet Rheumatol. 2022; 4 (6): e430–e440. doi:10.1016/S2665-9913(22)00096-0.Куликов А.Н., Муравьева Н.В., Белов Б.С. Безопасность вакцин против COVID-19 у больных с иммуновоспалительными ревматическими заболеваниями (предварительные данные). Современная ревматология. 2022; 16 (1): 26–31. https://doi.org/10.14412/1996-7012-2022-1-26-31.Kulikov A.N., Muravyeva N.V., Belov B.S. Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(1):26–31. https://doi.org/10.14412/1996-7012-2022-1-26-31. (in Russian)Буланов Н.М., Новиков П.И., Гуляев С.В. и др. Переносимость вакцины Гам-КОВИД- Вак (Спутник V) у взрослых пациентов с иммуновоспалительными ревматическими заболеваниями. Клиническая фармакология и терапия. 2021; 30 (4): 23–28. https://doi.org/10.32756/0869-5490-2021-4-23-28.Bulanov N., Novikov P., Gulyaev S. et al. Tolerability and safety of Gam-COVID-Vac (Sputnik V) vaccine in adult patients with autoimmune rheumatic diseases. Klinicheskaya Farmakologiya i Terapiya. 2021; 30 (4): 23–8. https://doi.org/10.32756/0869-5490-2021-4-23-28. (in Russian)

The authors declare that there are no conflicts of interest present.